65,437 trials
Healthy
Primary: Number of Subjects With Drug-related Adverse Events (AEs) — 1; 1; 2; 4 Participants
Healthy
Primary: Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 1780; 3680 Nanomol*Hour/Liter
Advanced Head and Neck Squamous Cell Carcinoma · Advanced Breast Cancer · Advanced Melanoma
Primary: Frequency, and Seriousness of TEAEs — 11; 19; 2; 0 number of events
Ulcerative Colitis
Primary: Reduction From Baseline in Modified Mayo Score (MMS) at Week 8 — -2.9; -3.2; -3.1; -1.9 Score
Healthy
Primary: Percentage of the Amount of [14C]-Radioactivity Excreted Among the Administered Single Oral Dose of [14-C] BI 1015550-EQ in Urine (Feurine, 0-tz), Faeces (Fefaeces…
Astrocytoma, Grade III · Glioblastoma
Primary: Maximum Tolerated Dose (MTD) — 150; 150 mg
Health Behavior
Primary: Goal Completion — 9; 9; 7; 9 Participants
Generalized Lipodystrophy
Primary: Evaluate the Immunogenicity Associated With Daily Subcutaneous (SC) Metreleptin Treatment in Patients With Congenital Generalized Lipodystrophy (CGL) or Acquired…
Health Behavior
Primary: Change in SF B Sleep Quality From Baseline to 6 Weeks — 2.73; 2.73; 2.98; 2.81 score on a scale — p=<0.0001
Machine Intelligence in the Pharmacy
Primary: Reaction Time — 3668; 4727; 4510 millisecond (ms)
Healthy Participants
Primary: Area Under the Plasma Concentration-time Curve From Time 0 to t (AUC[0-t]) for Minzasolmin — 5612; 5710; 6140 hour*nanograms per milliliter (h*ng/mL)
Multiple Sclerosis · Fatigue
Primary: Intervention Acceptability — 4.36; 4.64; 4.68 Units on a scale
Hepatitis B, Chronic
Primary: STRIVE and THRIVE: Proportion of Participants Achieving Suppression of HBV DNA (< LLOQ) With HBsAg Loss (< 0.05 IU/mL) at the End of Treatment — 1; 4 Participants
Postoperative Delirium · Hemodynamic Instability · Pain
Primary: Increase in Plasma IL-6 Levels — 15; 29.5; 80.5; 97.7 pg/mL
Nonalcoholic Steatohepatitis
Primary: Percentage of Participants Who Achieved ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 72 in Semaglutide (SEMA) +…